S&P assigns Cheplapharm loan, notes B

S&P said it assigned B ratings to Cheplapharm Arzneimittel GmbH’s proposed €100 million term loan B4 and proposed €400 million senior secured notes.

Proceeds from the loan and notes will be used for acquisitions.

S&P affirmed Cheplapharm’s B long-term issuer credit and issue ratings on Cheplapharm and the existing term loan B.

The outlook is stable.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.